Colorized scanning electron micrographs of natural killer cells from a human donor (Images: NIH / Graphics: Shehla Shakoor, Endpoints News)
November 12, 2019 03:22 PM ESTUpdated November 13, 10:23 AM
R&D

Kiadis aban­dons lead PhI­II pro­gram, shifts fo­cus to nat­ur­al killer cells

Jason Mast

Editor

Kiadis Phar­ma an­nounced that it is shift­ing fo­cus to nat­ur­al killer cells — and is it­self killing off the long-run­ning but deeply trou­bled Phase III ATIR …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times